Molecule Details
| InChIKey | CJAWPFJGFFNXQI-UHFFFAOYSA-N |
|---|---|
| Compound Name | 2-Chloro-6-(1-piperazinyl)pyrazine |
| Canonical SMILES | Clc1cncc(N2CCNCC2)n1 |
| Clinical Status | Data-mined Candidate |
| Targets (Human+Pathogen) | 4 |
| Pfam Stratification | Homologous |
| Avg pChEMBL | 6.53 |
| Source | BindingDB;ChEMBL |
2D Structure
Activity Profile
DrugBank Annotations
| DrugBank ID | DB12111 |
|---|---|
| Drug Name | MK-212 |
| CAS Number | 64022-27-1 |
| Groups | investigational |
| ATC Codes | nan |
| Description | MK-212 has been used in trials studying the treatment of Alcoholism. |
Categories: Antidepressive Agents Central Nervous System Depressants Neurotransmitter Agents Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome Serotonin Agents Serotonin Receptor Agonists
Cross-references: BindingDB: 50017452 ChEBI: 92360 CHEMBL269521 ChemSpider: 97104 PubChem:107992 PubChem:347828412 Wikipedia: MK-212 ZINC: ZINC000001571800
Target Activities (4)
DrugBank Target Actions (1)
| Target | Gene | Target Name | Action | Type |
|---|---|---|---|---|
| P28335 | HTR2C | 5-hydroxytryptamine receptor 2C | modulator | targets |